Astellas Pharma Inc (ALPMF) 16.6000 $ALPMF Vical Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMF) 16.6000 $ALPMF

Vical Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three and six months ended June 30, 2016. Net loss for the second quarter of 2016 was $1.3 million, or $0.14 per share, compared with a net loss of $2.8 million, or $0.30 per share, for the second quarter of 2015. Revenues for the second quarter of 2016 were $4.1 million, compared with revenues of $4.2 million for the second quarter of 2015, reflecting revenues from Astellas Pharma Inc. for manufacturing services performed under the ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.
VICL: 4.34 (-0.01)

Proteostasis Therapeutics Achieves Preclinical Milestone in Astellas Pharma Collaboration
GlobeNewswire - Mon Aug 08, 9:57AM CDT
Proteostasis Therapeutics, Inc. (NASDAQTI), a clinical stage biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, today announced that it has successfully completed a key preclinical milestone in its collaboration with Astellas Pharma Inc. (Astellas). The milestone, which triggered an undisclosed payment from Astellas, demonstrated that selective modulation of the Unfolded Protein Response (UPR) pathway in vitro is potentially an effective disease-modifying approach in the treatment of multiple diseases with few or no therapies currently available.
PTI: 13.00 (+0.12)

Avara Acquires Astellas U.S. Manufacturing Facility
PR Newswire - Wed Aug 03, 6:10PM CDT
Avara Pharmaceutical Services, Inc. announced that its subsidiary, Avara Norman Pharmaceutical Services, Inc. ("Avara" entered into an agreement under which Avara will acquire Astellas's wholly owned manufacturing subsidiary Astellas Pharma Technologies (APT), Inc., located in Norman, Oklahoma.

Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara
PR Newswire - Wed Aug 03, 6:00PM CDT
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" today announced that Astellas' US holding company, Astellas US Holding, Inc. ("Astellas US Holding", has transferred its wholly owned manufacturing subsidiary Astellas Pharma Technologies, Inc. (Location: Norman, OK, USA, "APT" to Avara Norman Pharmaceutical Services, Inc. (Headquarters: Norwalk, CT, USA, "Avara". Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital
BusinessWire - Thu Jul 28, 10:00PM CDT
Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas" and DigiTx Partners LLC (CEO: David Kim, "DigiTx Partners" announce that Astellas has launched DigiTx Partners, a digital health investment company in partnership with MPM Capital, Inc. ("MPM Capital". DigiTx Partners will invest in the digital health space broadly, with a special focus on companies which create solutions that improve patient outcomes and provide substantial synergy with a broader pharma business. Although the emphasis will be on earlier stage companies, investments will be made in both start-ups and growth stage companies.

FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
GlobeNewswire - Thu Jun 09, 6:00AM CDT
FibroGen, Inc. (Nasdaq:FGEN) ("FibroGen", announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc. (Astellas). This payment, which FibroGen expects to receive by July 2016, was triggered by the initiation by Astellas of the first Phase 3 clinical study in Japan of roxadustat (ASP1517 or FG-4592) for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis. Roxadustat, an orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI), is the most clinically advanced candidate in this new class of potential anemia therapeutic agents.
FGEN: 18.45 (+0.20)

Excelra Enters into a Drug Repurposing Collaboration with Astellas Pharma
BusinessWire - Tue Jun 07, 8:00AM CDT
Excelra, Asia's leading Knowledge Solutions Company, today announced that it has entered into a strategic Drug Repurposing collaboration with Tokyo-based pharmaceutical company, Astellas Pharma Inc. The collaboration is focused on identifying novel therapeutic indications for a number of undisclosed Astellas' shelved pharma assets.

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 46.50 (+0.74)

Global Endocarditis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, NexusCRO, Astellas Pharma - Research and Markets
BusinessWire - Thu Jun 02, 7:43AM CDT
Research and Markets has announced the addition of the "Endocarditis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 63.63 (+0.99)

Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 65.60 (+1.61)

Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
BusinessWire - Tue May 24, 7:00PM CDT
--Thunderbolt Pharma, Inc., will use technology to develop potential treatments for systemic lupus erythematosus and other B-cell mediated disorders
BXLT: 46.02 (-0.18)

Immunomic Therapeutics (ITI) Named "Company of the Year" by the Tech Council of Maryland
PR Newswire - Mon May 16, 11:14AM CDT
At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the state on Thursday night's industry celebration.

Global Varicella Zoster (HHV-3) Infections Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Astellas Pharma, Merck, TSRL - Research and Markets
BusinessWire - Wed May 11, 12:52PM CDT
Research and Markets has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2016" report to their offering.
MRK: 63.63 (+0.99)

Pipeline of Gastric Ulcers Market Reviewed for H1 2016 in New Global Research Report
PR Newswire - Mon May 02, 7:30AM CDT
New market research report titled "Gastric Ulcers - Pipeline Review, H1 2016" help enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Arterial Thrombosis Pipeline Report H1 2016 - Review of the Drug Profiles from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai Co., Johnson & Johnson & Sanofi - Research and Markets
BusinessWire - Fri Apr 29, 8:34AM CDT
Research and Markets has announced the addition of the "Arterial Thrombosis - Pipeline Review, H1 2016" report to their offering.
BMY: 61.27 (+0.30)

Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 5.70 (+0.87), CBMG: 13.49 (+0.11), OCAT: 8.47 (+0.01), ZBH: 129.50 (+0.58), PFE: 35.20 (+0.05), LLY: 80.56 (+0.01), GSK: 44.60 (+0.21), GLPG: 53.51 (+0.26), AXSM: 7.24 (-0.35), OMER: 11.37 (-1.50), CANF: 2.64 (+0.47), AST: 2.96 (+0.06), AKTX: 9.75 (-0.26)

Astellas and the CNTRP Continue Partnership and Commitment to Canadian Research Innovation
CNW Group - Wed Apr 27, 7:00AM CDT
Recipients of the second annual Research Innovation Grant competition announced

Astellas Oncology C3 Prize(TM) to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants
PR Newswire - Tue Apr 26, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) announced today the launch of the C3 Prize(TM), a challenge designed to inspire non-medicine innovations that improve the cancer care experience for patients, caregivers and loved ones. Entries will be accepted through August 8 and following a live pitch to a panel of judges including Robert Herjavec, star of ABC's Emmy Award-winning hit television show Shark Tank, three winners will be awarded a total of $100,000 in grants as well as membership to healthcare technology incubator MATTER to bring their ideas to life. The C3 Prize was announced to a group of 1,100 global leaders in cancer care gathered at the World Medical Innovation Forum organized by Partners HealthCare.

Astellas Pharma Canada Named as a Great Place to Work®
CNW Group - Fri Apr 22, 7:00AM CDT
Astellas Pharma Canada, Inc. (Astellas), the Canadian subsidiary of Tokyo based Astellas Pharma, Inc. (Tokyo: 4503), announced today that the company is being recognized as one of this year's Best Workplaces in Canada. The annual award, which is administered by the Great Place to Work(®) Institute Canada, recognizes employers across the country for creating and fostering exemplary workplace environments. This list, and related stories, will appear in a special national report on Friday, April 22, 2016 in The Globe and Mail.

CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
PR Newswire - Thu Apr 07, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a type II variation to include data from the head-to-head TERRAIN trial of enzalutamide versus bicalutamide in the European label for XTANDI® (enzalutamide) capsules.
MDVN: 65.60 (+1.61)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading